Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) SVP Martin E. Cearnal purchased 5,805 shares of the firm’s stock in a transaction that occurred on Monday, May 17th. The shares were acquired at an average cost of $2.83 per share, with a total value of $16,428.15. Following the completion of the purchase, the senior vice president now directly owns 148,814 shares in the company, valued at approximately $421,143.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Martin E. Cearnal also recently made the following trade(s):
- On Friday, May 7th, Martin E. Cearnal purchased 105 shares of Cumberland Pharmaceuticals stock. The shares were acquired at an average cost of $2.73 per share, with a total value of $286.65.
CPIX opened at $3.18 on Friday. The business’s fifty day moving average price is $2.91. The stock has a market cap of $47.86 million, a P/E ratio of -22.71 and a beta of 0.23. Cumberland Pharmaceuticals Inc. has a 52 week low of $2.58 and a 52 week high of $3.94. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.16 and a quick ratio of 1.72.
Large investors have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership purchased a new position in shares of Cumberland Pharmaceuticals in the 1st quarter valued at $32,000. M Holdings Securities Inc. purchased a new position in shares of Cumberland Pharmaceuticals in the 1st quarter valued at $33,000. Morgan Stanley increased its holdings in shares of Cumberland Pharmaceuticals by 131.3% in the 1st quarter. Morgan Stanley now owns 11,160 shares of the specialty pharmaceutical company’s stock valued at $34,000 after acquiring an additional 6,335 shares during the period. Citadel Advisors LLC purchased a new position in shares of Cumberland Pharmaceuticals in the 1st quarter valued at $52,000. Finally, Sterling Financial Planning Inc. purchased a new position in shares of Cumberland Pharmaceuticals in the 4th quarter valued at $65,000. Institutional investors and hedge funds own 21.44% of the company’s stock.
Several research firms have commented on CPIX. B. Riley restated a “buy” rating on shares of Cumberland Pharmaceuticals in a report on Monday, March 22nd. Zacks Investment Research upgraded Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price objective on the stock in a report on Tuesday, May 25th.
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections.
Further Reading: What are some reasons analysts would give stocks a buy rating?
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.